TB-500 Topical Lotion (0.25mg) delivers a low-dose, transdermal form of Thymosin Beta-4, a peptide studied for its role in cell migration, angiogenesis, and inflammation regulation. TB-500 is a synthetic analog known for promoting recovery in muscle, tendon, ligament, and skin tissue through its actin-binding and regenerative properties.

This topical formulation is ideal for localized research applications, where direct exposure to the skin or injury site is preferred. In preclinical models, TB-500 has demonstrated potential for accelerating recovery, reducing swelling, and supporting tissue remodeling at the site of damage.

How TB-500 Topical Works (Based on Preclinical Research):

• Modulates actin to support cellular repair and migration

• Enhances blood vessel formation (angiogenesis) to injured tissue

• Reduces local inflammation and oxidative stress markers

• Allows targeted peptide exposure via skin absorption

Potential Benefits (Based on Preclinical Research):

• Improved healing of localized muscle and tendon injuries

• Decreased joint inflammation and swelling

• Enhanced flexibility and tissue elasticity

• Suitable for dermatological, musculoskeletal, and orthopedic models

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory body and is intended solely for laboratory research.

The post TB-500 Topical 0.25mg (Pump) appeared first on Summit Edge Research.

GW-501516 Topical Lotion (0.5mg) delivers a research-grade formulation of GW-501516—also known as Cardarine—in a convenient, non-invasive topical format. GW-501516 is a PPARδ (peroxisome proliferator-activated receptor delta) agonist, studied for its ability to enhance fatty acid oxidation, increase endurance, and improve mitochondrial efficiency in muscle tissue.

The topical route offers the opportunity for localized application, making it ideal for studies involving targeted fat metabolism, muscle performance, or skin and subcutaneous lipid research. Preclinical models suggest GW-501516 may improve endurance and support lean body composition by promoting efficient energy utilization.

How GW-501516 Topical Works (Based on Preclinical Research):

• Activates PPARδ receptors in muscle and fat tissue to promote lipid metabolism

• Increases expression of genes involved in mitochondrial biogenesis and endurance

• Supports enhanced energy expenditure without stimulating the CNS

• Topical delivery allows for targeted absorption in localized research areas

Potential Benefits (Based on Preclinical Research):

• Improved fatty acid oxidation and energy efficiency

• Support for endurance and metabolic performance studies

• May aid in localized fat metabolism and skin-targeted lipid research

• Non-invasive format for repeated topical dosing

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory body and is intended solely for laboratory research.

The post GW-501516 Topical 0.5mg (Pump) appeared first on Summit Edge Research.

GHK-Cu Topical Lotion (500mcg) delivers a research-grade copper tripeptide complex directly to the skin for targeted preclinical studies on wound healing, skin regeneration, and inflammation modulation. GHK-Cu (glycyl-L-histidyl-L-lysine:copper) is a naturally occurring peptide known for its ability to stimulate collagen and elastin production, improve tissue remodeling, and protect cells from oxidative stress.

Topical delivery allows the compound to act directly at the application site, making it ideal for research involving scarring, ulceration, dermal repair, and anti-aging models.

How GHK-Cu Topical Lotion Works (Based on Preclinical Research):

• Binds bioavailable copper ions to promote tissue regeneration and repair

• Stimulates fibroblast activity and supports collagen/elastin synthesis

• Reduces local inflammation and oxidative stress markers

• Enhances angiogenesis and skin barrier function at the site of application

Potential Benefits (Based on Preclinical Research):

• Accelerated healing of wounds, burns, and ulcers

• Improved skin elasticity, firmness, and appearance

• Anti-inflammatory and antioxidant effects in local tissue

• Support for dermal remodeling and anti-aging studies

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory body and is intended solely for laboratory research.

The post GHK-CU Topical 500mcg (Pump) appeared first on Summit Edge Research.

BPC-157 / TB-500 Topical Lotion (15mg) delivers a powerful combination of two peptides—BPC-157, derived from a natural gastric protein, and TB-500, a synthetic analog of Thymosin Beta-4. Together, these compounds have been studied for their synergistic effects on tissue regeneration, inflammation reduction, and wound healing, particularly in muscle, ligament, tendon, and skin applications.

This topical formulation allows direct application to target areas in preclinical studies, bypassing systemic delivery routes and focusing research on localized recovery and repair.

How the BPC-157 / TB-500 Topical Blend Works (Based on Preclinical Research):

• BPC-157: Modulates inflammatory pathways and promotes angiogenesis and fibroblast migration

• TB-500: Regulates actin and enhances cell migration and blood flow in damaged tissue

• Topical route provides localized exposure and penetration to injury sites

• May accelerate healing in soft tissue and dermal models

Potential Benefits (Based on Preclinical Research):

• Enhanced localized healing of skin, tendons, and ligaments

• Reduced inflammation and oxidative damage

• Improved flexibility and soft tissue recovery

• Non-invasive delivery format ideal for dermatological and orthopedic models

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory body and is intended solely for laboratory research.

The post BPC-157/TB-500 Topical 15mg (Pump) appeared first on Summit Edge Research.

Tirzepatide 30mg is a synthetic peptide designed as a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This combination has been studied for its enhanced metabolic effects over GLP-1 agonists alone, including improved insulin sensitivity, appetite suppression, and significant body weight reduction in preclinical models.

Tirzepatide mimics the action of two key incretin hormones to promote glucose-dependent insulin secretion, delay gastric emptying, and modulate central appetite-regulating pathways. It is widely researched in models of type 2 diabetes, obesity, and metabolic syndrome.

How Tirzepatide Works (Based on Preclinical Research):

• Activates both GIP and GLP-1 receptors to enhance insulin response and satiety

• Reduces food intake and delays gastric emptying

• Improves glucose regulation and insulin sensitivity

• Offers superior weight loss outcomes compared to single-pathway agonists

Potential Benefits (Based on Preclinical Research):

• Significant reductions in body weight and food consumption

• Improved glycemic control in insulin-resistant models

• Enhanced lipid metabolism and fat loss

• Advanced support for obesity and metabolic disorder studies

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory body and is intended solely for laboratory research.

The post Tirzepatide 30mg appeared first on Summit Edge Research.

Tirzepatide 10mg is a synthetic peptide designed as a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This combination has been studied for its enhanced metabolic effects over GLP-1 agonists alone, including improved insulin sensitivity, appetite suppression, and significant body weight reduction in preclinical models.

Tirzepatide mimics the action of two key incretin hormones to promote glucose-dependent insulin secretion, delay gastric emptying, and modulate central appetite-regulating pathways. It is widely researched in models of type 2 diabetes, obesity, and metabolic syndrome.

How Tirzepatide Works (Based on Preclinical Research):

• Activates both GIP and GLP-1 receptors to enhance insulin response and satiety

• Reduces food intake and delays gastric emptying

• Improves glucose regulation and insulin sensitivity

• Offers superior weight loss outcomes compared to single-pathway agonists

Potential Benefits (Based on Preclinical Research):

• Significant reductions in body weight and food consumption

• Improved glycemic control in insulin-resistant models

• Enhanced lipid metabolism and fat loss

• Advanced support for obesity and metabolic disorder studies

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory body and is intended solely for laboratory research.

The post Tirzepatide 10mg appeared first on Summit Edge Research.

Tirzepatide 5mg is a synthetic peptide designed as a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This combination has been studied for its enhanced metabolic effects over GLP-1 agonists alone, including improved insulin sensitivity, appetite suppression, and significant body weight reduction in preclinical models.

Tirzepatide mimics the action of two key incretin hormones to promote glucose-dependent insulin secretion, delay gastric emptying, and modulate central appetite-regulating pathways. It is widely researched in models of type 2 diabetes, obesity, and metabolic syndrome.

How Tirzepatide Works (Based on Preclinical Research):

• Activates both GIP and GLP-1 receptors to enhance insulin response and satiety

• Reduces food intake and delays gastric emptying

• Improves glucose regulation and insulin sensitivity

• Offers superior weight loss outcomes compared to single-pathway agonists

Potential Benefits (Based on Preclinical Research):

• Significant reductions in body weight and food consumption

• Improved glycemic control in insulin-resistant models

• Enhanced lipid metabolism and fat loss

• Advanced support for obesity and metabolic disorder studies

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory body and is intended solely for laboratory research.

The post Tirzepatide 5mg appeared first on Summit Edge Research.

The Tesofensine / AOD-9604 Blend delivers a dual-action research compound designed to target multiple metabolic pathways associated with weight regulation, fat loss, and energy balance. Tesofensine is a triple monoamine reuptake inhibitor studied for its ability to reduce appetite and increase energy levels by enhancing dopaminergic, serotonergic, and noradrenergic activity. AOD-9604, a modified peptide fragment of human growth hormone, has been shown in preclinical studies to stimulate lipolysis and inhibit lipogenesis without affecting insulin or IGF-1 levels.

This combination is designed to explore central appetite suppression alongside peripheral fat metabolism, offering a comprehensive approach to weight management research.

How the Tesofensine / AOD-9604 Blend Works (Based on Preclinical Research):

• Tesofensine: Inhibits reuptake of dopamine, norepinephrine, and serotonin to reduce appetite and increase energy

• AOD-9604: Mimics the fat-burning region of HGH to stimulate lipolysis and prevent new fat accumulation

• Synergistic action may result in reduced caloric intake and enhanced fat oxidation

• Suitable for research models of obesity, metabolic syndrome, and body recomposition

Potential Benefits (Based on Preclinical Research):

• Appetite suppression with enhanced satiety signaling

• Increased fat breakdown and metabolic rate

• Reduced visceral and subcutaneous fat mass

• Improved energy balance without significant hormonal disruption

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory body and is intended solely for laboratory research.

The post Tesofensine/AOD-9604 appeared first on Summit Edge Research.